PapersFlow Research Brief
Prenatal Screening and Diagnostics
Research Guide
What is Prenatal Screening and Diagnostics?
Prenatal screening and diagnostics refers to techniques and methods for detecting prenatal aneuploidy and chromosomal abnormalities, including maternal plasma DNA sequencing, noninvasive prenatal testing, preimplantation genetic diagnosis, and fetal DNA analysis.
This field encompasses 1,672,437 works focused on diagnosing conditions such as trisomy through cell-free DNA and genomic sequencing. Key advancements include the detection of fetal DNA in maternal plasma, as shown in early studies. Techniques like enzymatic amplification of genomic sequences enable rapid prenatal tests for disorders including sickle cell anemia.
Topic Hierarchy
Research Sub-Topics
Noninvasive Prenatal Testing
This sub-topic covers cell-free fetal DNA analysis from maternal plasma for aneuploidy detection using next-generation sequencing and other molecular techniques. Researchers study test accuracy, validation across populations, and integration into clinical workflows.
Cell-Free Fetal DNA Analysis
Focuses on the biology, quantification, and sequencing of cell-free fetal DNA in maternal blood for diagnostic applications. Researchers investigate fetal fraction determination, contamination issues, and advanced analytical methods.
Preimplantation Genetic Diagnosis
Examines biopsy techniques, genetic testing methods like PCR and NGS on embryos during IVF for selecting unaffected ones. Researchers develop protocols to minimize mosaicism errors and improve implantation success rates.
Chromosomal Microarray Analysis
Involves array CGH and SNP arrays for detecting copy number variations and microdeletions in prenatal samples. Researchers compare resolution with karyotyping and establish clinical guidelines for variant interpretation.
Trisomy Detection Methods
Covers quantitative PCR, SNP-based sequencing, and methylation analyses specifically for trisomies 21, 18, and 13. Researchers optimize sensitivity, specificity, and false-positive reduction strategies.
Why It Matters
Prenatal screening identifies chromosomal abnormalities like trisomies 21, 18, and 13 early in pregnancy, enabling informed reproductive decisions; multiple studies identify cell-free DNA (cfDNA) as superior to traditional serum and ultrasound methods. Genome-wide non-invasive prenatal testing (GW-NIPT) as a first-tier screen detected fetal aneuploidy and copy number variations in a cohort of 59,771 pregnancies. Clinical modeling shows GW-NIPT offers economic benefits over targeted NIPT and first-trimester combined testing. Tools like NIPTeR R package support NIPT analysis of cell-free fetal DNA via next-generation sequencing.
Reading Guide
Where to Start
"Presence of fetal DNA in maternal plasma and serum" (1997) by Lo et al., as it foundational discovery enabled noninvasive prenatal testing using maternal blood.
Key Papers Explained
"Enzymatic Amplification of β-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia" (1985) by Saiki et al. introduced PCR-based amplification for prenatal diagnosis, with 8984 citations. "Presence of fetal DNA in maternal plasma and serum" (1997) by Lo et al. (3004 citations) built on this by detecting fetal DNA noninvasively. "To err (meiotically) is human: the genesis of human aneuploidy" (2001) by Hassold and Hunt (2470 citations) explained underlying mechanisms of aneuploidy targeted by these diagnostics.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Genome-wide NIPT evaluated in 59,771 pregnancies assesses aneuploidy and CNV performance. Preprints discuss expanding NIPT scope using cfDNA epigenetic features and clinical-economic modeling of first-tier GW-NIPT. FDA granted Breakthrough Device Designation to GeneDx for prenatal applications.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Enzymatic Amplification of β-Globin Genomic Sequences and Rest... | 1985 | Science | 9.0K | ✕ |
| 2 | Mortality In Sickle Cell Disease -- Life Expectancy and Risk F... | 1994 | New England Journal of... | 3.3K | ✓ |
| 3 | Presence of fetal DNA in maternal plasma and serum | 1997 | The Lancet | 3.0K | ✕ |
| 4 | Consensus Statement: Chromosomal Microarray Is a First-Tier Cl... | 2010 | The American Journal o... | 2.8K | ✓ |
| 5 | Strong Association of De Novo Copy Number Mutations with Autism | 2007 | Science | 2.8K | ✓ |
| 6 | High-Throughput Droplet Digital PCR System for Absolute Quanti... | 2011 | Analytical Chemistry | 2.7K | ✓ |
| 7 | To err (meiotically) is human: the genesis of human aneuploidy | 2001 | Nature Reviews Genetics | 2.5K | ✕ |
| 8 | Elective induction versus spontaneous labor after sonographic ... | 1993 | PubMed | 2.4K | ✕ |
| 9 | Genomic imprinting: parental influence on the genome | 2001 | Nature Reviews Genetics | 2.3K | ✕ |
| 10 | High resolution analysis of DNA copy number variation using co... | 1998 | Nature Genetics | 2.2K | ✕ |
In the News
BrightHeart Raises €11M Series A to Scale Expert-Level AI ...
PARIS--( BUSINESS WIRE )-- **BrightHeart** , a global leader in artificial intelligence (AI) solutions for prenatal ultrasound, today announced the closing of an**€11 million Series A financing rou...
FDA Grants Breakthrough Device Designation for Whole ...
## **Clinical Applications**
GeneDx receives FDA Breakthrough Device Designation ...
Prenatal acid-suppressive medications not linked to neuropsychiatric disorders | Image Credit: ©Halfpoint - ©Halfpoint - stock.adobe.com.
Diagnostic Foundation Models, Expanded Genetic Testing, ...
GeneDxis looking upstream of pediatrics as well.GeneDxreported breakthrough results from its Guardian newborn screening study in New York, where 3.2% of tested babies had clinically actionable gene...
NIH Ends Funding for Human Fetal Tissue Research
Webinar Thumbnail [ From Bottleneck to Breakthroughs: Solving Everyday Assay Headaches with Intelligent Liquid Handling
Code & Tools
_Hoobari_ _(Hebrew: hoo - him, bari - healthy, oobari - fetal)_ is the first fetal variant calling program, designed to prenataly find SNPs (single...
DuPLUS: A dual-prompt vision-language framework for universal medical image segmentation across multiple datasets and modalities using hierarchical...
Non-Invasive Prenatal Testing (NIPT) is a method based on analysis of cell-free fetal (cff) DNA in maternal blood using next-generation sequencing....
Source repository for the Fetal Records FHIR implementation guide ## About Source repository for the Fetal Records FHIR implementation guide ### Re...
# THIS REPO IS NOT CURRENTLY MAINTAINED # PETDiagnostics The goal of PETDiagnostics is to assess feasibility of data sources to perform observa...
Recent Preprints
Screening for Fetal Chromosomal Abnormalities
“Multiple studies have identified cfDNA as a superior screening test for trisomies 21, 18, and 13 compared with traditional serum and ultrasound
Clinical and economic impact of genome-wide non-invasive prenatal testing (NIPT) as a first-tier screening method compared to targeted NIPT and first-trimester combined testing: A modeling study
- Prenatal screening aims to detect fetal chromosomal abnormalities, such as Down syndrome, early in pregnancy to help expectant parents make informed reproductive choices.
Advancements in Prenatal Genetic Screening and Testing: Emerging Technologies and Evolving Applications
Advancements in genomic technologies have transformed prenatal genetic testing, offering more accurate, comprehensive, and noninvasive approaches to reproductive care. This review provides an in-de...
Expanding the scope of non-invasive prenatal screening
Non-invasive prenatal screening has swiftly been implemented as a first- or second-tier test for common fetal aneuploidies and typically relies on sequencing maternal circulating cell-free DNA (cfD...
Clinical experience of genome-wide non-invasive prenatal testing as a first-tier screening test in a cohort of 59,771 pregnancies
### Objective Genome-wide non-invasive prenatal testing (GW-NIPT) for prenatal screening has been widely implemented. However, the related clinical data is still insufficient. Here, we evaluated th...
Latest Developments
Recent developments in prenatal screening and diagnostics include advancements in non-invasive prenatal testing (NIPT), with the market valued at USD 5.37 billion in 2025 and projected to reach USD 16.94 billion by 2034 (straitsresearch.com). Innovations are also focusing on expanding the scope of screening methods, such as the development of single-gene non-invasive prenatal tests (sgNIPT) for conditions like cystic fibrosis and sickle cell disease, with a study ending around February 2026 (UCSF trial). Additionally, recent guidelines endorsed by ACOG and SMFM emphasize improved use of cfDNA screening, reflecting ongoing efforts to refine accuracy and application (ACOG, SMFM). Emerging research also explores high-resolution fetal exome sequencing and expanded genetic screening techniques, including NGS-based approaches (NEJM, nature.com).
Sources
Frequently Asked Questions
What is noninvasive prenatal testing (NIPT)?
NIPT analyzes cell-free fetal DNA in maternal blood using next-generation sequencing to screen for aneuploidies such as trisomies 21, 18, and 13. The NIPTeR R package facilitates this by processing sequencing data from maternal plasma. It provides higher accuracy than traditional serum and ultrasound screening.
How was fetal DNA first detected in maternal plasma?
Lo et al. (1997) demonstrated the presence of fetal DNA in maternal plasma and serum. This discovery enabled noninvasive methods for prenatal analysis. It forms the basis for modern cfDNA-based screening.
What role does enzymatic amplification play in prenatal diagnosis?
Saiki et al. (1985) developed primer-mediated enzymatic amplification of β-globin sequences, achieving a 220,000-fold increase in target DNA for sickle cell anemia diagnosis. This method established rapid prenatal testing. It amplified specific genomic regions for restriction site analysis.
What is genome-wide NIPT?
Genome-wide NIPT screens for fetal aneuploidy and copy number variations using maternal cfDNA as a first-tier test. A study in 59,771 pregnancies evaluated its clinical performance. It expands beyond common trisomies to broader genomic variants.
How does chromosomal microarray fit in prenatal diagnostics?
Miller et al. (2010) stated chromosomal microarray is a first-tier test for individuals with developmental disabilities or congenital anomalies. It detects copy number variations relevant to prenatal findings. This consensus supports its diagnostic use.
Open Research Questions
- ? How can epigenetic features of cell-free DNA improve detection of genetic findings beyond common aneuploidies?
- ? What is the clinical performance of GW-NIPT for rare copy number variations in large cohorts?
- ? How do de novo copy number mutations contribute to prenatal chromosomal abnormalities?
- ? What meiotic errors primarily cause human aneuploidy in prenatal diagnoses?
- ? How can droplet digital PCR enhance absolute quantitation for fetal DNA copy number assessment?
Recent Trends
Cell-free DNA screening outperforms traditional methods for trisomies 21, 18, and 13, per recent preprints.
GW-NIPT implemented as first-tier test in 59,771 pregnancies.
BrightHeart raised €11M for AI prenatal ultrasound solutions.
Research Prenatal Screening and Diagnostics with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Prenatal Screening and Diagnostics with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers